Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:


	Six Months Ended
	June 30,
	2020		2019

Employee and director stock option grants:
Research and development	$	27,213	$	26,003
General and administrative		209,576		483,122
Total stock-based compensation	$	236,789	$	509,125

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


				Weighted
	Number of			Average
	Shares Issuable			Remaining
	Upon Exercise	Weighted		Contracted	Aggregate
	of Outstanding	Average		Term in	Intrinsic
	Options	Exercise Price		Years	Value
Outstanding at December 31, 2019	610,714	$	6.78	8.83	$	34,750
Granted	553,750	$	1.92
Forfeited	(80,000)	$	2.46
Outstanding at June 30, 2020	1,084,464	$	4.62	8.99	$	—

Exercisable, June 30, 2020	375,658	$	9.55	8.10	$	—
Unvested, June 30, 2020	708,806	$	2.00	9.46	$	—

Schedule of Restricted Stock Grants

The following table summarizes the restricted stock grants:


		Weighted
		Average
		Grant Date		Total Grant
	Number of	Fair Value		Date Fair
	Shares	Per Share		Value
Outstanding at December 31, 2019	9,334	$	21.00	$	196,000
Vested	(9,334)	$	21.00	$	(196,000)
Outstanding at June 30, 2020	—	$	—	$	—